Ligand Pharmaceuticals Inc.
3911 Sorrento Valley Boulevard
473 articles with Ligand Pharmaceuticals Inc.
Ligand Pharmaceuticals Incorporated announced plans to report second quarter 2018 financial results on August 6, 2018.
Ligand Receives $47 Million from WuXi Biologics for Expansion of Worldwide OmniAb® Platform License Agreement
Updates 2018 Full Year and Second Quarter Financial Guidance
Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report first quarter 2018 financial results on May 8, 2018. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call.
Ligand Enters into Agreement with venBio to Make Worldwide OmniAb® Platform License Accessible to Portfolio Companies
venBio’s portfolio companies will be able to use the full OmniAb platform including OmniRat®, OmniMouse®, OmniFlic® and OmniChicken™ to discover fully human mono- and bispecific antibodies.
Ligand Pharmaceuticals is licensing LGD-6972, a glucagon receptor antagonist (GRA), to Roivant Sciences for $20 million.
Ligand Pharmaceuticals Inc. announced the signing of a license agreement granting Roivant Sciences exclusive global rights to develop and commercialize LGD-6972, Ligand’s glucagon receptor antagonist (GRA).
Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call.
Under the license, Ferring will be able to use the full OmniAb platform including OmniRat®, OmniMouse®, OmniFlic® and OmniChicken™ to discover fully human mono- and bispecific antibodies.
Under the agreement, Ferring will use OmniAb to accelerate development solutions for unmet patient needs in reproductive medicine and women’s health, urology and gastroenterology.
Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Contrast Agents for Diagnostic Imaging
The program will leverage Ligand’s patented Captisol technology, as well as data and intellectual property obtained through its acquisition of Verrow Pharmaceuticals.
Under the license, Glenmark will be able to use the full OmniAb platform including OmniChicken, OmniRat, OmniMouse and OmniFlic to discover fully human mono- and multispecific antibodies.
Under the license agreements with HanAll, Ligand is eligible to receive milestones and royalties on the successful development of antibodies and to share sub-license revenue on out-licensed antibodies.
Nobody is interested in slow-growth or no-growth stocks, long term or short term, but everyone's interested in fast-growing stocks.
The webcast is available at www.ligand.com.
Total revenues for the third quarter of 2017 were $33.4 million, compared with $21.6 million for the same period in 2016.
Ligand Pharmaceuticals Incorporated announced today that it plans to report third quarter 2017 financial results after market close on November 9, 2017 and to provide additional commentary during its Analyst Day.
When you think about it, most small biotech companies are odd investments.
Ligand Scoops Up Bay Area's Crystal Bioscience In $25 Million Cash Plus Additional Potential Payments Deal